{"id":56098,"date":"2023-04-21T19:03:32","date_gmt":"2023-04-21T17:03:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/"},"modified":"2023-04-21T19:03:32","modified_gmt":"2023-04-21T17:03:32","slug":"bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/","title":{"rendered":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com<\/a><\/b>:<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\nNine Months Ended<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nThree Months Ended<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\nFebruary 28,<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nFebruary 28,<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2023<\/span><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2022<\/span><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2023<\/span><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2022<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\nRevenue<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n46,595,270<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n47,806,600<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n14,107,568<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n17,132,276<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nIncome Before Income Tax<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n2,174,295<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n4,767,636<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1,610,199<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n1,210,288<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nNet (Loss) Income<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n1,537,695<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n3,373,036<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1,139,699<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n856,588<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nBasic Earnings per Share<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nof Common Stock<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n1.72<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n3.77<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1.27<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n0.96<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nDiluted Earnings per Share<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nof Common Stock<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n1.72<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n3.77<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1.27<\/p>\n<\/td>\n

\n

\n)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n0.96<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nWeighted Average<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nNumber of Shares Outstanding<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nFor Basic Earnings Per Share<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nWeighted Average<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nNumber of Shares Outstanding<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nFor Diluted Earnings Per Share<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,426<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,408<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,431<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nFor more detail related to the fiscal year 2023 unaudited third quarter results, please visit our web site at www.bioqual.com<\/a>.<\/p>\n

\nStatements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company\u2019s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company\u2019s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company\u2019s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company\u2019s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing\/capital sources to the Company.<\/p>\n

Contacts<\/b> <\/p>\n

\nMark G. Lewis, Ph.D., CEO (240-404-7654)<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com: \u00a0 Nine Months Ended \u00a0 Three Months Ended February 28, \u00a0 February 28, \u00a0 2023 \u00a0 \u00a0 2022 \u00a0 \u00a0 2023 \u00a0 \u00a0 \u00a0 2022 Revenue $ 46,595,270 $ 47,806,600 $ 14,107,568 \u00a0 $ 17,132,276 \u00a0 Income Before Income Tax $ 2,174,295 $ 4,767,636 $ (1,610,199 ) $ … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56098","6":"format-standard","7":"category-industry"},"yoast_head":"\nBIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com: \u00a0 Nine Months Ended \u00a0 Three Months Ended February 28, \u00a0 February 28, \u00a0 2023 \u00a0 \u00a0 2022 \u00a0 \u00a0 2023 \u00a0 \u00a0 \u00a0 2022 Revenue $ 46,595,270 $ 47,806,600 $ 14,107,568 \u00a0 $ 17,132,276 \u00a0 Income Before Income Tax $ 2,174,295 $ 4,767,636 $ (1,610,199 ) $ ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T17:03:32+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023\",\"datePublished\":\"2023-04-21T17:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/\"},\"wordCount\":310,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/\",\"name\":\"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-21T17:03:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/","og_locale":"en_US","og_type":"article","og_title":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (OTC Pink:BIOQ) www.bioqual.com: \u00a0 Nine Months Ended \u00a0 Three Months Ended February 28, \u00a0 February 28, \u00a0 2023 \u00a0 \u00a0 2022 \u00a0 \u00a0 2023 \u00a0 \u00a0 \u00a0 2022 Revenue $ 46,595,270 $ 47,806,600 $ 14,107,568 \u00a0 $ 17,132,276 \u00a0 Income Before Income Tax $ 2,174,295 $ 4,767,636 $ (1,610,199 ) $ ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-21T17:03:32+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023","datePublished":"2023-04-21T17:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/"},"wordCount":310,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/","url":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/","name":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-21T17:03:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-third-quarter-of-fiscal-year-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56098"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56098\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}